Résumé
Background@#and Purpose Patients with aortic disease might have an increased risk of intracranial aneurysm (IA). We conducted this research to assess the prevalence of IA in patients with aortopathy, considering the impact of gender, age, and cardiovascular risk factors. @*Methods@#We searched PubMed and Scopus from inception to August 2019 for epidemiological studies reporting the prevalence of IA in patients with aortopathy. Random-effect meta-analyses were performed to calculate the overall prevalence, and the effect of risk factors on the prevalence was also evaluated. Anatomical location of IAs in patients suffered from distinct aortic disease was extracted and further analyzed. @*Results@#Thirteen cross-sectional studies involving 4,041 participants were included in this systematic review. We reported an estimated prevalence of 12% (95% confidence interval [CI], 9% to 14%) of IA in patients with aortopathy. The pooled prevalence of IA in patients with bicuspid aortic valve, coarctation of the aorta, aortic aneurysm, and aortic dissection was 8% (95% CI, 6% to 10%), 10% (95% CI, 7% to 14%), 12% (95% CI, 9% to 15%), and 23% (95% CI, 12% to 34%), respectively. Gender (female) and smoking are risk factors related to an increased risk of IA. The anatomical distribution of IAs was heterogeneously between participants with different aortic disease. @*Conclusions@#According to current epidemiological evidence, the prevalence of IA in patients with aortic disease is quadrupled compared to that in the general population, which suggests that an early IA screening should be considered among patients with aortic disease for timely diagnosis and treatment of IA.
Résumé
OBJECTIVE:To evaluate therapeutic efficacy of Shengxuening tablets in the treatment of iron-deficiency anemia during pregnancy,so as to provide evidence for clinical decisions. METHODS:Retrieved from CNKI,Wanfang,VIP and PubMed,clinical randomized controlled trials(RCTs)about Shengxuening tablets in the treatment of iron-deficiency anemia during pregnancy were collected during 2008-2018. After screening literatures and extracted information, the literature quality was evaluated by using improved Jadad scale. Meta-analyses was performed by using Stata 12.0 software. RESULTS:A total of 11 RCTs were included,inulving 1 617 patients. Total response rate of Shengxuening tablets was significantly higher than those of ferrous sulfate [OR＝8.73,95%CI(2.964,25.69),P＜0.05],ferrous succinate [OR＝1.86,95%CI(1.04,3.33),P＜0.05] and dietory conditioning [OR＝3.43,95%CI(2.08,5.66),P＜0.05],with statistical significance. CONCLUSIONS:Therapeutic efficacy of Shengxuening tablets is significantly better than that of routine iron supplements in the treatment of iron-deficiency anemia during pregnancy.